8:00 AM GMT, Dec 13, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact firstname.lastname@example.org.
One byproduct of recent development successes in metastatic renal cell carcinoma has been the emergence of questions about how best to use the various drugs. A variety of head-to-head studies are underway, and the first direct comparison of targeted agents was provided last month by Pfizer Inc., which reported axitinib met the primary endpoint of a Phase III trial, significantly improved progression-free survival vs. Nexavar sorafenib in second-line RCC.
Pfizer did not disclose detailed data on the pan-VEGF receptor tyrosine kinase inhibitor (TKI) because it plans to present the results at a scientific meeting in 1H11.
Glen Andrews, an asset team leader in Pfizer's oncology business unit, told
Read the full 1068 word article